Dear Colleague,
GTC is proud to announce its inaugural Immunogenicity and Immunotoxicity
Conference, one of four parallel tracks to the
2nd Novel Immunotherapeutics Summit on January 31 - February 1, 2013 San
Diego, CA. This is the West Coast's first 2 day conference that brings together
leading experts in industry, academia and the FDA. The inaugural conference will
cover important progress made in the areas of therapeutic protein immunogenicity
and immunotoxicity evaluation such as protein aggregation, clinical relevance
and assessment of immunogenicity, mitigation of immunogenicity-related risks,
biosimilar development, and immunotoxicity evaluation strategies. In addition to
4 internationally recognized experts in the field of Immunogenicity and
Immunotoxicity speaking at this year’s Inaugural conference, what will you gain
by attending this conference?
- A better understanding of the ongoing research for tools to mitigate risks
associated with the immunogenicity of therapeutic proteins.
- An up-to-date understanding of the mechanisms and consequences of protein
aggregation.
- Insights on how to prosecute state-of-the-art assessment of the clinical
immunogenicity of therapeutic proteins.
- In-depth information on current practices of immunotoxicity evaluation.
With Southern California home to a number of industry leaders, this event
promises to become the west coast's premiere conference. We look forward to
seeing you in the warm California sunshine.
Sessions for 2013 to Include:
Immunogenicity Prediction, Causes, Mitigation and Strategies
Protein Aggregation Biological Activity and Immunogenicity
Immunogenicity Assessment for Biosimilars
Clinical Relevance
Risk Assessment and Management
Toxicity of Immune Modulators
Immunotoxicity Evaluation of Novel Drug Candidates
To view the agenda,
click here.
To view the speaker list,
click here.
2nd Novel
Immunotherapeutics Summit:
Workshop: Immune
Responses in Tumor Microenvironment
Immunogenicity and Immunotoxicity
5th Immunotherapeutics & Immunomonitoring
2nd Allergy & Respiratory Drug Discovery
11 Cytokines and Inflammation
Sign up for the summit pass to have access to both tracks of the summit. Or
bring a team of 3 for the price of 2 by
registering with the coupon code rcdvb!
We look forward to seeing you at the conference!
|
|
PLATINUM
SPONSOR |
|
 |
|
|
SILVER SPONSOR |
|
 |
|
 |
|
 |
|
|
MEDIA PARTNERS |
|
 |
|
| |
What Past Delegates said:
"Energizing and inspiring conference. The new ideas and connections are worth
the investment."
- Francisco Leon, VP, Janssen R&D
"The GTC Meeting provided a unique opportunity for a select group of scientists
from biotechnology, pharmaceutical companies and academia to communicate and
interact in a very pleasant setting. The program covered not only fundamental
advances, but also translational and diagnostic applications of the latest
findings."
- Joost J. Oppenheim Chief of the Laboratory of Molecular Immunoregulation,
Cancer and Inflammation Program, NCI, NIH
"The GTC Novel Immunotherapeutics Summit was a great opportunity to meet
industry and academic leaders. The networking opportunities were ideal for
meaningful exchanges and setting up potential collaborations. "
- Yoav Peretz Ph.D., Principal Scientist, ImmuneCarta Services
"The GTC conference definitely provided a private, common, and friendly setting
to exchange ideas and opinions with industry and academia leaders. Networking
really happens at this conference with relevant and exciting topics. I left the
GTC conference with fresh ideas and with new connections for future
partnerships. "
- Mario Pulido, USC |
|
|
Jacques Descotes
Professor and Head, Poison Center and
Pharmacovigilance
Lyon University General Hospitals |
Jack Ragheb
Principal Investigator Laboratory of Immunology
Therapeutic Proteins Office of Biological Products
CDER, FDA |
StevenSwanson
Executive Director
Amgen |
